To learn more about the APOLLO trial, please visit [ Ссылка ] or [ Ссылка ]
Presented at ACC as a Late-Breaking Clinical Trial, the Cleveland Clinic-led APOLLO trial explores siRNA therapy as a treatment option to help prevent premature heart disease in people with high levels of Lp(a). This condition is estimated to affect 64 million people in the United States and 1.4 billion people worldwide. It is estimated that nearly 20 to 25% of the world’s population has elevated Lp(a). Dr. Steven Nissen explains the purpose, patient selection, and findings of APOLLO.
To learn more about Steven Nissen, MD, Cleveland Clinic Heart, Vascular & Thoracic Institute Chief Academic Officer, please visit [ Ссылка ]
To read the full article, please visit [ Ссылка ]
▶Share this video with others: [ Ссылка ]
▶Subscribe to learn more about Cleveland Clinic:
[ Ссылка ]
#ClevelandClinic #ConsultQD #ApolloTrial
